Known targets — ChEMBL curated mechanism
CACNA1BGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BMAOBSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Ralfinamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A known ✓ | Q15858 | 2/20 | 0.98 |
| ▸ | MAOB known ✓ | P27338 | 8/20 | 0.65 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.65 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.56 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ralfinamide SCHEMBL1697252 | 1.00 | SCN9A (0.98) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL67329 | 0.99 | SCN9A (1.00) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL29379049 | 0.99 | SCN9A (1.00) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL67328 | 0.99 | SCN9A (1.00) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL962699 | 0.99 | SCN9A (1.00) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL1697229 | 0.94 | SCN9A (0.91) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL1697234 | 0.94 | SCN9A (0.91) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL1697241 | 0.94 | SCN9A (0.91) | SCN9AMAOBMAOASCN3APARP15 | |
| SCHEMBL963787 | 0.91 | SCN9A (0.85) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL5567624 | 0.90 | SCN9A (0.82) | SCN9AMAOBMAOASCN3APARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856207-B2 | Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2018-01-02 | — | — | US | disclosed |
| US-20170029365-A1 | PROCESS FOR THE PRODUCTION OF RALFINAMIDE SALTS SUBSTANTIALLY FREE FROM IMPURITIES HAVING GENOTOXIC EFFECTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2017-02-02 | — | — | US | disclosed |
| US-9505708-B2 | Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-11-29 | — | — | US | disclosed |
| EP-2563355-B1 | Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers | NEWRON PHARM SPA (IT) | 2016-06-08 | — | — | EP | disclosed |
| EP-2563355-A1 | PROCESS FOR THE PRODUCTION OF RALFINAMIDE METHANESULFONATE SALTS OR THEIR R-ENANTIOMERS | Newron Pharmaceuticals S.p.A. (IT) | 2013-03-06 | — | — | EP | disclosed |
| US-20130039983-A1 | PROCESS FOR THE PRODUCTION OF RALFINAMIDE SALTS SUBSTANTIALLY FREE FROM IMPURITIES HAVING GENOTOXIC EFFECTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-02-14 | — | — | US | disclosed |
| WO-2011134763-A1 | PROCESS FOR THE PRODUCTION OF RALFINAMIDE METHANESULFONATE SALTS OR THEIR R-ENANTIOMERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029365-A1 | PROCESS FOR THE PRODUCTION OF RALFINAMIDE SALTS SUBSTANTIALLY FREE FROM IMPURITIES HAVING GENOTOXIC EFFECTS | RALA, KRAS, RAP2C | SCN9A 2723/4885MAOB 4062/4885SCN3A 1079/4885 |
| US-20130039983-A1 | PROCESS FOR THE PRODUCTION OF RALFINAMIDE SALTS SUBSTANTIALLY FREE FROM IMPURITIES HAVING GENOTOXIC EFFECTS | RALA, HRAS, CYP2F1 | SCN9A 2330/4885MAOB 4406/4885SCN3A 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.